Boston Trust Walden Corp Grows Holdings in Abbott Laboratories $ABT

Boston Trust Walden Corp raised its position in Abbott Laboratories (NYSE:ABT) by 48.0% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 70,256 shares of the healthcare product maker’s stock after purchasing an additional 22,799 shares during the period. Boston Trust Walden Corp’s holdings in Abbott Laboratories were worth $7,213,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ABT. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $95.25 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a fifty day moving average price of $88.95 and a two-hundred day moving average price of $104.35. The company has a market cap of $165.91 billion, a PE ratio of 26.68, a P/E/G ratio of 1.64 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period last year, the firm posted $1.09 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. Abbott Laboratories’s dividend payout ratio is 70.59%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ABT. JPMorgan Chase & Co. dropped their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Weiss Ratings downgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Argus cut their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Stifel Nicolaus reduced their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Finally, Robert W. Baird started coverage on Abbott Laboratories in a research note on Wednesday. They issued an “outperform” rating and a $121.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $118.42.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.